Radioligand Therapy Targets in Cervical Cancer
We screened every cell-surface protein with tumor immunohistochemistry data in cervical cancer (including cervical squamous cell carcinoma). 4,191 show detectable protein staining. Established and emerging radioligand targets expressed in cervical cancer include HER3 (ERBB3), c-MET (MET), ITGB6 and EGFR. Below, we rank every candidate by tumor expression, internalization and clinical maturity.
Established and emerging radioligand targets in cervical cancer
Targets already pursued with radioligands or other targeted modalities that show protein expression in cervical cancer:
| Target | IHC in cervical cancer | % positive | Internalizes |
|---|---|---|---|
| HER3 (ERBB3) | High (0.72) | 100% | yes |
| c-MET (MET) | High (0.72) | 100% | yes |
| ITGB6 | High (0.64) | 100% | — |
| EGFR | High (0.61) | 92% | yes |
| STEAP2 | High (0.58) | 92% | — |
| CEA (CEACAM5) | High (0.58) | 91% | — |
| ITGAV | High (0.53) | 100% | — |
| B7-H3 (CD276) | Medium (0.50) | 92% | — |
| TMEFF2 | Medium (0.44) | 75% | — |
| EPCAM | Medium (0.42) | 73% | — |
| Nectin-4 (NECTIN4) | Medium (0.42) | 83% | no |
| FAP | Medium (0.41) | 56% | yes |
| TROP2 (TACSTD2) | Medium (0.36) | 64% | uncertain |
| SSTR2 | Medium (0.31) | 75% | yes |
| Mesothelin (MSLN) | Medium (0.28) | 58% | yes |
| Claudin 18.2 (CLDN18) | Low (0.08) | 8% | uncertain |
| HER2 (ERBB2) | Low (0.03) | 10% | yes |
| CAIX (CA9) | Low (0.03) | 9% | no |
| CD38 | Low (0.03) | 8% | — |
Top cell-surface targets for cervical cancer radioligand therapy
A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.
| # | Target | IHC in cervical cancer | % positive | Internalizes | Clinical stage |
|---|---|---|---|---|---|
| 1 | IGF1R insulin like growth factor 1 receptor | High (0.86) | 100% | yes | Clinical |
| 2 | c-MET (MET) MET proto-oncogene, receptor tyrosine kinase | High (0.72) | 100% | yes | Clinical |
| 3 | EGFR epidermal growth factor receptor | High (0.61) | 92% | yes | Clinical |
| 4 | S1PR1 sphingosine-1-phosphate receptor 1 | High (0.61) | 100% | yes | Clinical |
| 5 | AGTRAP angiotensin II receptor associated protein | High (0.97) | 100% | yes | Discovery |
| 6 | AMFR autocrine motility factor receptor | High (0.97) | 100% | yes | Discovery |
| 7 | FZD6 frizzled class receptor 6 | High (0.94) | 100% | yes | Discovery |
| 8 | HER3 (ERBB3) erb-b2 receptor tyrosine kinase 3 | High (0.72) | 100% | yes | Clinical |
| 9 | GPR139 G protein-coupled receptor 139 | High (0.92) | 100% | yes | Discovery |
| 10 | NOTCH1 notch receptor 1 | High (0.69) | 100% | yes | Clinical |
| 11 | HRH4 histamine receptor H4 | High (0.67) | 100% | yes | Clinical |
| 12 | TREM1 triggering receptor expressed on myeloid cells 1 | High (0.78) | 100% | uncertain | Clinical |
| 13 | LSR lipolysis stimulated lipoprotein receptor | High (0.82) | 100% | yes | Discovery |
| 14 | NR3C2 nuclear receptor subfamily 3 group C member 2 | High (0.78) | 100% | uncertain | Clinical |
| 15 | MAOB monoamine oxidase B | High (0.90) | 100% | — | Clinical |
| 16 | IRAK4 interleukin 1 receptor associated kinase 4 | High (0.64) | 100% | yes | Clinical |
| 17 | LIFR LIF receptor subunit alpha | High (0.77) | 100% | yes | Discovery |
| 18 | IL1R2 interleukin 1 receptor type 2 | High (0.61) | 92% | yes | Discovery |
| 19 | SCTR secretin receptor | High (0.88) | 100% | uncertain | Discovery |
| 20 | FGFR1 fibroblast growth factor receptor 1 | High (0.56) | 92% | yes | Clinical |
| 21 | TNFRSF1A TNF receptor superfamily member 1A | High (0.58) | 100% | yes | Clinical |
| 22 | MFGE8 milk fat globule EGF and factor V/VIII domain containing | High (1.00) | 100% | — | Discovery |
| 23 | ADGRL1 adhesion G protein-coupled receptor L1 | High (0.76) | 91% | yes | Discovery |
| 24 | BCL2L2-PABPN1 BCL2L2-PABPN1 readthrough | High (1.00) | 100% | — | Clinical |
| 25 | MUC1 mucin 1, cell surface associated | High (1.00) | 100% | — | Clinical |
Internalizing receptors in cervical cancer
Targets expressed in cervical cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:
IGF1R · c-MET (MET) · EGFR · S1PR1 · AGTRAP · AMFR · FZD6 · HER3 (ERBB3) · GPR139 · NOTCH1 · HRH4 · LSR
Cervical Cancer targets already in clinical development
Targets with a clinical-stage drug program (any modality) that are also expressed in cervical cancer. Clinical precedent lowers development risk but usually means more competition:
IGF1R · c-MET (MET) · EGFR · S1PR1 · HER3 (ERBB3) · NOTCH1 · HRH4 · TREM1 · NR3C2 · MAOB · IRAK4 · FGFR1
How these cervical cancer targets are ranked
Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in cervical cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.
Rank cervical cancer targets against your own criteria: isotope, organ limits, novelty.
Run a free cervical cancer analysisRadioligand therapy targets in other cancers
- Prostate Cancer
- Neuroendocrine Tumors
- Lung Cancer
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Kidney Cancer
- Bladder Cancer
- Gastric Cancer
- Liver Cancer
- Glioma
- Melanoma
- Head and Neck Cancer
- Thyroid Cancer
- Lymphoma
- Endometrial Cancer
- Skin Cancer
- Testicular Cancer
Data sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.